CriticalAntidepressants. Other antidepressants of herbal origin×Triptan, selective 5HT1B/1D receptor agonist
Updated · Methodology
Mechanism
St John's wort extract inhibits the synaptosomal reuptake of serotonin, noradrenaline and dopamine (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Naratriptan is a selective serotonin 5-HT1 receptor agonist (naratriptan SmPC, AEMPS, section 5.1). The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with triptans, including naratriptan (St John's wort SmPC, AEMPS, section 4.5). The naratriptan SmPC also states that adverse reactions may be more frequent when triptans are used with St John's wort preparations (naratriptan SmPC, AEMPS, section 4.4). Naratriptan undergoes limited metabolism: half of the dose is excreted unchanged in the urine. In vitro, many cytochrome P450 isoenzymes take part in its metabolism. For this reason, the naratriptan SmPC does not anticipate significant metabolic interactions (naratriptan SmPC, AEMPS, sections 4.5 and 5.2).
Symptoms
The St John's wort summary of product characteristics (SmPC) warns of increased serotonergic effects and more frequent adverse reactions when St John's wort is combined with triptans (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). According to the European Medicines Agency (EMA) herbal monograph, serotonin syndrome can occur very rarely in combination with serotonin reuptake inhibitors or other serotonergic substances (St John's wort herbal monograph, EMA, section 4.5). Serotonin syndrome may occur with naratriptan, particularly with selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), tricyclic antidepressants and monoamine oxidase (MAO) inhibitors (naratriptan label, US Food and Drug Administration, FDA, section 5.7). St John's wort is not on this list. According to this label, signs include agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyperreflexia, incoordination, nausea, vomiting and diarrhoea. They usually appear within minutes to hours of a new or higher dose of a serotonergic medicine (FDA naratriptan label, section 5.7).
Management
The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with medicines of the triptan group, and its interaction table names naratriptan (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The naratriptan documents are less strict. The Spanish naratriptan SmPC states that adverse reactions may be more frequent with St John's wort preparations but does not prohibit the combination (naratriptan SmPC, AEMPS, section 4.4). The naratriptan label of the US Food and Drug Administration (FDA) does not mention St John's wort. If the two have nevertheless been taken together and serotonin syndrome is suspected, stop naratriptan (FDA naratriptan label, section 5.7). No document says how long to wait between stopping St John's wort and taking naratriptan.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Naratriptán (nº registro 61828), sección 4.3 (2023)– AEMPS, CIMA, nº registro 61828 (Naramig 2,5 mg, Glaxo), revisión 11/2023 (fecha del documento en CIMA; la sección 10 indica junio 2020), secciones 4.3, 4.4 y 4.5
- FDA: Naratriptan tablets, Bionpharma (naratriptan) prescribing information (2026)– FDA, DailyMed setid 93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda, revisión 06/2026 (versión 4), secciones 4, 5.1–5.8 y 7.1
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5